Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy

Neuropharmacology

Volumn 109, Issue , 2016, Pages 69-77

  Engeln, Michel ^a,b   Ansquer, Solène ^c,d   Dugast, Emilie ^c,d,e   Bezard, Erwan ^a,b   Belin, David ^e,f,g   Fernagut, Pierre Olivier ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE POITIERS   (France)

^e INSERM   (France)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alpha synuclein; Impulsivity; Parkinson; Pramipexole; Substantia nigra

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; PRAMIPEXOLE; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; DOPAMINE REPLACEMENT THERAPY; DOPAMINERGIC NERVE CELL; IMPULSE CONTROL DISORDER; IMPULSIVENESS; INHIBITION (PSYCHOLOGY); MALE; MOTOR ACTIVITY; MOTOR CONTROL; NEUROPHYSIOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STRIATONIGRAL DEGENERATION; SUBSTITUTION THERAPY; UPREGULATION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; INSTRUMENTAL CONDITIONING; METABOLISM; NERVE DEGENERATION; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA;

ANIMALS; CONDITIONING, OPERANT; DOPAMINE; DOPAMINE AGONISTS; DOPAMINERGIC NEURONS; IMPULSIVE BEHAVIOR; MALE; NERVE DEGENERATION; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

EID: 84976550586     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2016.05.013     Document Type: Article

References (48)

1. Antonelli, F., Ko, J.H., Miyasaki, J., Lang, A.E., Houle, S., Valzania, F., Ray, N.J., Strafella, A.P., Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions. Hum. Brain Mapp. 35:6 (2014 Jun), 2499–2506, 10.1002/hbm.22344.
2. Basar, K., Sesia, T., Groenewegen, H., Steinbusch, H.W., Visser-Vandewalle, V., Temel, Y., Nucleus accumbens and impulsivity. Prog. Neurobiol. 92 (2010), 533–557.
3. Bastiaens, J., Dorfman, B.J., Christos, P.J., Nirenberg, M.J., Prospective cohort study of impulse control disorders in Parkinson's disease. Mov. Disord. 28 (2013), 327–333.
4. Bourdenx, M., Dovero, S., Engeln, M., Bido, S., Bastide, M.F., Dutheil, N., Vollenweider, I., Baud, L., Piron, C., Grouthier, V., Boraud, T., Porras, G., Li, Q., Baekelandt, V., Scheller, D., Michel, A., Fernagut, P.O., Georges, F., Courtine, G., Bezard, E., Dehay, B., Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by alpha-synuclein overexpression. Acta Neuropathol. Commun., 3, 2015, 46.
5. Buckholtz, J.W., Treadway, M.T., Cowan, R.L., Woodward, N.D., Li, R., Ansari, M.S., Baldwin, R.M., Schwartzman, A.N., Shelby, E.S., Smith, C.E., Kessler, R.M., Zald, D.H., Dopaminergic network differences in human impulsivity. Science, 329, 2010, 532.
6. Caprioli, D., Hong, Y.T., Sawiak, S.J., Ferrari, V., Williamson, D.J., Jupp, B., Adrian Carpenter, T., Aigbirhio, F.I., Everitt, B.J., Robbins, T.W., Fryer, T.D., Dalley, J.W., Baseline-dependent effects of cocaine pre-exposure on impulsivity and D2/3 receptor availability in the rat striatum: possible relevance to the attention-deficit hyperactivity syndrome. Neuropsychopharmacology 38 (2013), 1460–1471.
7. Cawley, E.I., Park, S., aan het Rot, M., Sancton, K., Benkelfat, C., Young, S.N., Boivin, D.B., Leyton, M., Dopamine and light: dissecting effects on mood and motivational states in women with subsyndromal seasonal affective disorder. J. Psychiatry Neurosci. 38 (2013), 388–397.
8. Cools, R., Barker, R.A., Sahakian, B.J., Robbins, T.W., L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 41 (2003), 1431–1441.
9. D'Amour-Horvat, V., Leyton, M., Impulsive actions and choices in laboratory animals and humans: effects of high vs. low dopamine states produced by systemic treatments given to neurologically intact subjects. Front. Behav. Neurosci., 8, 2014, 432.
10. Dagher, A., Robbins, T.W., Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 61 (2009), 502–510.
11. Dalley, J.W., Mar, A.C., Economidou, D., Robbins, T.W., Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry. Pharmacol. Biochem. Behav. 90 (2008), 250–260.
12. Dalley, J.W., Roiser, J.P., Dopamine, serotonin and impulsivity. Neuroscience 215 (2012), 42–58.
13. Engeln, M., Ahmed, S.H., Vouillac, C., Tison, F., Bezard, E., Fernagut, P.O., Reinforcing properties of Pramipexole in normal and parkinsonian rats. Neurobiol. Dis. 49C (2012), 79–86.
14. Engeln, M., Bastide, M.F., Toulme, E., Dehay, B., Bourdenx, M., Doudnikoff, E., Li, Q., Gross, C.E., Boue-Grabot, E., Pisani, A., Bezard, E., Fernagut, P.O., Selective inactivation of striatal FosB/DeltaFosB-expressing neurons alleviates L-dopa-induced dyskinesia. Biol. Psychiatry 79:5 (2016 Mar 1), 354–361, 10.1016/j.biopsych.2014.07.007.
15. Engeln, M., Fasano, S., Ahmed, S.H., Cador, M., Baekelandt, V., Bezard, E., Fernagut, P.O., L-dopa gains psychostimulant-like properties after nigral dopaminergic loss. Ann. Neurol. 74 (2013), 140–144.
16. Evenden, J.L., The pharmacology of impulsive behaviour in rats II: the effects of amphetamine, haloperidol, imipramine, chlordiazepoxide and other drugs on fixed consecutive number schedules (FCN 8 and FCN 32). Psychopharmacol. Berl. 138 (1998), 283–294.
17. Fletcher, P.J., Effects of combined or separate 5,7-dihydroxytryptamine lesions of the dorsal and median raphe nuclei on responding maintained by a DRL 20s schedule of food reinforcement. Brain Res. 675 (1995), 45–54.
18. Frank, M.J., Seeberger, L.C., O'Reilly, R.C., By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 306 (2004), 1940–1943.
19. Gotham, A.M., Brown, R.G., Marsden, C.D., ’Frontal’ cognitive function in patients with Parkinson's disease ’on’ and ’off’ levodopa. Brain 111:Pt 2 (1988), 299–321.
20. Hill, J.C., Covarrubias, P., Terry, J., Sanabria, F., The effect of methylphenidate and rearing environment on behavioral inhibition in adult male rats. Psychopharmacol. Berl. 219 (2012), 353–362.
21. Jentsch, J.D., Ashenhurst, J.R., Cervantes, M.C., Groman, S.M., James, A.S., Pennington, Z.T., Dissecting impulsivity and its relationships to drug addictions. Ann. N. Y. Acad. Sci. 1327 (2014), 1–26.
22. Johnson, P.S., Madden, G.J., Brewer, A.T., Pinkston, J.W., Fowler, S.C., Effects of acute pramipexole on preference for gambling-like schedules of reinforcement in rats. Psychopharmacol. Berl. 213 (2011), 11–18.
23. Mallet, N., Ballion, B., Le Moine, C., Gonon, F., Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats. J. Neurosci. 26 (2006), 3875–3884.
24. Murray, J.E., Belin-Rauscent, A., Simon, M., Giuliano, C., Benoit-Marand, M., Everitt, B.J., Belin, D., Basolateral and central amygdala differentially recruit and maintain dorsolateral striatum-dependent cocaine-seeking habits. Nat. Commun., 6, 2015, 10088.
25. Nombela, C., Rittman, T., Robbins, T.W., Rowe, J.B., Multiple modes of impulsivity in Parkinson's disease. PLoS One, 9, 2014, e85747.
26. Pena-Oliver, Y., Buchman, V.L., Dalley, J.W., Robbins, T.W., Schumann, G., Ripley, T.L., King, S.L., Stephens, D.N., Deletion of alpha-synuclein decreases impulsivity in mice. Genes Brain Behav. 11 (2012), 137–146.
27. Pena-Oliver, Y., Sanchez-Roige, S., Stephens, D.N., Ripley, T.L., Alpha-synuclein deletion decreases motor impulsivity but does not affect risky decision making in a mouse Gambling Task. Psychopharmacol. Berl. 231 (2014), 2493–2506.
28. Piray, P., Zeighami, Y., Bahrami, F., Eissa, A.M., Hewedi, D.H., Moustafa, A.A., Impulse control disorders in Parkinson's disease are associated with dysfunction in stimulus valuation but not action valuation. J. Neurosci. 34 (2014), 7814–7824.
29. Poletti, M., Bonuccelli, U., Impulse control disorders in Parkinson's disease: the role of personality and cognitive status. J. Neurol. 259 (2012), 2269–2277.
30. Rivalan, M., Gregoire, S., Dellu-Hagedorn, F., Reduction of impulsivity with amphetamine in an appetitive fixed consecutive number schedule with cue for optimal performance in rats. Psychopharmacol. Berl. 192 (2007), 171–182.
31. Rokosik, S.L., Napier, T.C., Pramipexole-induced increased probabilistic discounting: comparison between a rodent model of Parkinson's disease and controls. Neuropsychopharmacology 37 (2012), 1397–1408.
32. Sanabria, F., Killeen, P.R., Evidence for impulsivity in the Spontaneously Hypertensive Rat drawn from complementary response-withholding tasks. Behav. Brain Funct., 4, 2008, 7.
33. Tang, J., Strafella, A.P., The frontostriatal circuitry and behavioral complications in PD. Park. Relat. Disord. 18:Suppl. 1 (2012), S104–S106.
34. Tedford, S.E., Persons, A.L., Napier, T.C., Dopaminergic lesions of the dorsolateral striatum in rats increase delay discounting in an impulsive choice task. PLoS One, 10, 2015, e0122063.
35. Todes, C.J., Lees, A.J., The pre-morbid personality of patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 48 (1985), 97–100.
36. van Gaalen, M.M., Brueggeman, R.J., Bronius, P.F., Schoffelmeer, A.N., Vanderschuren, L.J., Behavioral disinhibition requires dopamine receptor activation. Psychopharmacol. Berl. 187 (2006), 73–85.
37. Voon, V., Fernagut, P.O., Wickens, J., Baunez, C., Rodriguez, M., Pavon, N., Juncos, J.L., Obeso, J.A., Bezard, E., Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol. 8 (2009), 1140–1149.
38. Voon, V., Fox, S.H., Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch. Neurol. 64 (2007), 1089–1096.
39. Voon, V., Gao, J., Brezing, C., Symmonds, M., Ekanayake, V., Fernandez, H., Dolan, R.J., Hallett, M., Dopamine agonists and risk: impulse control disorders in Parkinson's disease. Brain 134 (2011), 1438–1446.
40. Voon, V., Hassan, K., Zurowski, M., Duff-Canning, S., de Souza, M., Fox, S., Lang, A.E., Miyasaki, J., Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66 (2006), 1750–1752.
41. Voon, V., Mehta, A.R., Hallett, M., Impulse control disorders in Parkinson's disease: recent advances. Curr. Opin. Neurol. 24 (2011), 324–330.
42. Voon, V., Pessiglione, M., Brezing, C., Gallea, C., Fernandez, H.H., Dolan, R.J., Hallett, M., Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 65 (2010), 135–142.
43. Voon, V., Reynolds, B., Brezing, C., Gallea, C., Skaljic, M., Ekanayake, V., Fernandez, H., Potenza, M.N., Dolan, R.J., Hallett, M., Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacol. Berl. 207 (2010), 645–659.
44. Voon, V., Schoerling, A., Wenzel, S., Ekanayake, V., Reiff, J., Trenkwalder, C., Sixel-Doring, F., Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol., 11, 2011, 117.
45. Vriend, C., Gerrits, N.J., Berendse, H.W., Veltman, D.J., van den Heuvel, O.A., van der Werf, Y.D., Failure of stop and go in de novo Parkinson's disease-a functional magnetic resonance imaging study. Neurobiol. Aging 36 (2015), 470–475.
46. Weintraub, D., Impulse control disorders in Parkinson's disease: prevalence and possible risk factors. Park. Relat. Disord. 15:Suppl. 3 (2009), S110–S113.
47. Weintraub, D., Koester, J., Potenza, M.N., Siderowf, A.D., Stacy, M., Voon, V., Whetteckey, J., Wunderlich, G.R., Lang, A.E., Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 67 (2010), 589–595.
48. Weintraub, D., Papay, K., Siderowf, A., Parkinson's Progression Markers, I, Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 80 (2013), 176–180.